Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elevance HealthWBO:ELV +1.94%82 Cyclically Adjusted PB Ratio is 2.25 as of Aug. 06, 2026, which is 25% below its 10-year median of 3.01. GuruFocus rates WBO:ELV with a GF Score™ of 82/100 and a GF Value™ of €420.35 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 13 Healthcare Plans companies, Elevance Health ranks worse than 53.85% on this metric.
The historical rank and industry rank for Elevance Health's Cyclically Adjusted PB Ratio or its related term are showing as below:
WBO:ELV'
s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.67 Med: 3.01 Max: 4.28
Current: 2.3
During the past years, Elevance Health's highest Cyclically Adjusted PB Ratio was 4.28. The lowest was 1.67. And the median was 3.01.
WBO:ELV's Cyclically Adjusted PB Ratio is ranked worse than 53.85% of 13
companies
in the Healthcare Plans industry
Industry Median: 2.3
vs WBO:ELV: 2.30
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
Elevance Health's adjusted book value per share data for the three months ended in Jun. 2026 was €179.664. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €149.28 for the trailing ten years ended in Jun. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Elevance Health (WBO:ELV) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Elevance Health Cyclically Adjusted PB Ratio Related Terms
Elevance Health Cyclically Adjusted PB Ratio Historical Data
* Premium members only.
The historical data trend for Elevance Health's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elevance Health Cyclically Adjusted PB Ratio Chart
WBO:ELV vs CI, HUM, CNC: Cyclically Adjusted PB Ratio Comparison
For the Healthcare Plans subindustry, Elevance Health's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elevance Health Cyclically Adjusted PB Ratio vs Healthcare Plans Industry
For the Healthcare Plans industry and Healthcare sector, Elevance Health's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where Elevance Health's Cyclically Adjusted PB Ratio falls into.
Elevance Health Cyclically Adjusted PB Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
Elevance Health's Cyclically Adjusted PB Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PB Ratio of 2.25 mean?
Elevance Health (WBO:ELV) has a Cyclically Adjusted PB Ratio of 2.25 as of Aug. 06, 2026. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Elevance Health and its competitors. This is 25% below median its historical median of 3.01. Over the past decade, Elevance Health's Cyclically Adjusted PB Ratio has ranged from 1.67 to 4.28. According to the industry distribution chart, Elevance Health ranks #7 out of 13 companies in the Healthcare Plans industry, placing it in the top 53.8%.
Is Elevance Health's Cyclically Adjusted PB Ratio too high?
Elevance Health's current Cyclically Adjusted PB Ratio of 2.25 is 25% below median its 10-year median of 3.01. Over the past 10 years, this metric has ranged from a low of 1.67 to a high of 4.28. The Healthcare Plans industry median Cyclically Adjusted PB Ratio is 2.30. Elevance Health's value of 2.25 is 2.2% below this industry median. Based on the distribution chart, Elevance Health ranks #7 out of 13 companies in the Healthcare Plans industry, which is below the industry midpoint. Overall, Elevance Health has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elevance Health's Cyclically Adjusted PB Ratio compare to CI and HUM?
According to the Healthcare Plans industry distribution chart, Elevance Health ranks #7 out of 13 companies for Cyclically Adjusted PB Ratio. This places Elevance Health in the lower half of its industry. The industry median Cyclically Adjusted PB Ratio is 2.30. Elevance Health's value of 2.25 is 2.2% below this benchmark. Historically, Elevance Health's own Cyclically Adjusted PB Ratio has ranged from 1.67 to 4.28 over the past decade. While the company's 10-year median is 3.01 vs. the industry median of 2.30, Elevance Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PB Ratio for a Healthcare Plans company?
The median Cyclically Adjusted PB Ratio among Healthcare Plans companies is 2.30, based on 13 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elevance Health's current Cyclically Adjusted PB Ratio of 2.25 is 2.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PB Ratio mean?
A high Cyclically Adjusted PB Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PB Ratio is the ratio of share price to a company's inflation-adjusted book value per share over a 10-year period. View historical data on Elevance Health and its competitors. For the Healthcare Plans industry, the median Cyclically Adjusted PB Ratio is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elevance Health's current Cyclically Adjusted PB Ratio is 2.25, which is 25% below median its own 10-year median of 3.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elevance Health stock overvalued right now?
Based on GuruFocus' analysis, Elevance Health (WBO:ELV) is currently considered Modestly Undervalued. The stock's GF Value™ is €420.35, compared to a current price of €335.80 — trading 20.1% below its estimated fair value. The current Cyclically Adjusted PB Ratio is 2.25, which is 25% below median its 10-year median of 3.01 and 2.2% below the Healthcare Plans industry median of 2.30. Elevance Health's overall GF Score™ is 82/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PB Ratio calculated?
Cyclically Adjusted PB Ratio is calculated from a company's financial statements. For Elevance Health (WBO:ELV), the current Cyclically Adjusted PB Ratio is 2.25 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elevance Health (WBO:ELV) Overvalued in 2026?
Based on GuruFocus' analysis, Elevance Health stock appears to be undervalued.
The current stock price of €335.80 is trading 20.1% below its estimated GF Value™ of €420.35.
GuruFocus considers Elevance Health to be Modestly Undervalued.
Key valuation signals for WBO:ELV:
Cyclically Adjusted PB Ratio: 2.25 (25% below median its 10-year median of 3.01)
GF Value™: €420.35 vs. price of €335.80 (20.1% below fair value)
Industry Position: 2.2% below the Healthcare Plans median (#7 of 13)
No single metric tells the full story. See the WBO:ELV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
82GF Score
Get the complete analysis for WBO:ELV
Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:ELV has been successfully added to your 
